Encora Therapeutics Receives FDA 510(k) Clearance for Wearable Essential Tremor Device
核心洞察
Encora Therapeutics (搜索) has received FDA 510(k) clearance for the Encora X1 (搜索), a wrist-worn neurostimulation device for essential tremor (搜索) treatment.
The clearance is supported by two clinical studies demonstrating consistent improvements in tremor severity and functional tasks for daily activities.
The device offers a non-invasive, drug-free alternative for the 7 million Americans with essential tremor (搜索) who often find medications ineffective.
Encora Therapeutics (搜索) announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Encora X1 (搜索), a breakthrough wearable device designed to provide relief for adults with essential tremor (搜索). The clearance authorizes commercial marketing of the prescription device to aid in the relief of hand tremors in the treated limb during stimulation.
Clinical Evidence Supporting Approval
The FDA clearance is supported by data from two clinical studies: a randomized, sham-controlled trial and a 90-day home-use study. These studies demonstrated consistent improvements in tremor severity and functional tasks, showcasing the device's ability to aid in daily activities such as eating, drinking, and writing.
"The data demonstrate meaningful improvement in tremor severity and functional outcomes for patients with limited options," said Ann Murray, M.D., principal investigator and chief of the WVU Rockefeller Neuroscience Institute (搜索) Comprehensive Movement Disorder Center. "For the 7 million Americans suffering from essential tremor (搜索), medications are often ineffective or poorly tolerated, leaving invasive brain therapy as the only alternative. Non-invasive technologies like this represent an important area of innovation in the treatment of essential tremor."
Device Technology and Mechanism
The Encora X1 (搜索) is a noninvasive, wrist-worn neurostimulation device, roughly the size of a smart watch, designed to sense tremor rhythm and deliver customized stimulation that disrupts the tremor signal. The device provides patients with stability and improved motor control during daily activities, such as drinking soup with a spoon, dialing a telephone, or plugging a cord into an electric outlet.
The device utilizes proprietary algorithms to analyze a patient's tremor in real time and delivers targeted stimulation to the wrist, modulating the neural pathways (搜索) responsible for the tremor. The device is lightweight, discreet, and allows for seamless integration into daily life, ensuring that relief is available when needed most.
Addressing Unmet Medical Need
"We started Encora with a simple goal: to restore independence for movement disorder patients. Today, we are one step closer to making that vision a reality," said Alli Davanzo, Co-Founder and Vice President of Business Operations. "Encora X1 (搜索) offers a non-surgical, drug-free alternative, allowing patients to manage their symptoms on their own terms."
Nadim Yared, Chief Executive Officer of Encora Therapeutics (搜索), emphasized the significance of the milestone: "This clearance represents the culmination of rigorous research and patient-centric design. We are eager to bring this novel solution to patients who have long waited for more options."
Safety Profile
The Encora X1 (搜索) is available by prescription only and is not a cure for essential tremor (搜索). In clinical trials, device-related adverse events were non-serious and self-resolving. Reported side effects include numbness, skin irritation (rash), muscle weakness, discomfort/pain, buzzing/tingling sensation, and possible temporary worsening of tremor. Federal law restricts this device to sale by or on the order of a physician.
Encora Therapeutics (搜索), founded by graduates of the Massachusetts Institute of Technology and headquartered in Boston, MA, is a leading innovator in neuromodulation technology dedicated to developing non-invasive solutions to improve the lives of individuals with movement disorders.